Cabozantinib S-Malate 1140909-48-3: Targeted Therapy for Advanced Cancers
A leading tyrosine kinase inhibitor for advanced renal cell and thyroid carcinoma treatment.
Get a Quote & SampleProduct Core Value
Cabozantinib S-Malate
Cabozantinib S-Malate (CAS 1140909-48-3) is a highly effective small molecule inhibitor targeting multiple receptor tyrosine kinases (RTKs) essential for cancer progression. It plays a crucial role as a tyrosine kinase inhibitor in cancer therapy.
- Research into MET and VEGFR2 inhibitor mechanisms is vital for developing effective treatments for various cancers.
- This potent antineoplastic agent facilitates novel cancer therapy approaches by blocking key signaling pathways.
- The high purity and consistent quality of Cabozantinib S-Malate are crucial for reliable pharmaceutical research and development.
- Discovering new applications for small molecule kinase inhibitors like this is at the forefront of modern oncology research.
Key Advantages
Targeted Kinase Inhibition
Cabozantinib S-Malate acts as a MET and VEGFR2 inhibitor, crucial for combating tumor growth and angiogenesis, offering a precise approach in cancer therapy.
Broad Anti-Cancer Spectrum
This pharmaceutical chemical is instrumental in advanced renal cell carcinoma treatment and medullary thyroid cancer drug development, highlighting its role in oncology.
High Purity and Quality
Ensuring the highest standards for this antineoplastic agent is paramount for its use in clinical trials and pharmaceutical research, supporting innovative cancer therapy.
Key Applications
Oncology Research
Essential for studies focusing on targeted cancer therapies and understanding the role of receptor tyrosine kinases in disease progression. Leverages MET and VEGFR2 inhibitor properties.
Pharmaceutical Development
Serves as a key active pharmaceutical ingredient (API) for developing new anti-cancer drugs, particularly for advanced renal cell carcinoma treatment.
Medullary Thyroid Cancer Treatment
A critical component in formulations designed to treat medullary thyroid cancer, demonstrating its value as a specific medullary thyroid cancer drug.
Clinical Trials
Used extensively in clinical trials to evaluate its efficacy and safety in patients with various advanced carcinomas, supporting the development of novel cancer therapy.